论文部分内容阅读
目的:探讨氨磷汀对中、晚期直肠癌术后,FOLFOX4方案化疗过程中患者重要脏器的保护作用。方法:选择直肠癌根治术后临床中、晚期(Ⅱ、Ⅲ期)的直肠癌患者60例,随机分为两组,化疗组和氨磷汀+化疗组,均治疗4周期。结果:对比两组不良反应发生率,化疗组和氨磷汀+化疗组显著低于化疗组,二者差异具有统计学意义(P<0.05)。结论:氨磷汀可显著降低FOLFOX4方案化疗的不良反应发生率,对患者重要脏器具有保护作用。
Objective: To investigate the protective effects of amifostine on postoperative patients with moderate and advanced rectal cancer, and during FOLFOX4 regimen chemotherapy. METHODS: A total of 60 patients with rectal cancer in the middle and late stage (stages II and III) after radical resection of rectal cancer were randomly divided into two groups. The chemotherapy group and amifostine plus chemotherapy group were treated for 4 cycles. Results: The incidence of adverse reactions in the two groups was significantly lower in the chemotherapy group and the amifostine plus chemotherapy group than in the chemotherapy group (P<0.05). CONCLUSION: Amifostine can significantly reduce the incidence of adverse reactions to chemotherapy with the FOLFOX4 regimen and has protective effects on important organs.